レジオネラ検査の世界市場-2022-2029

市場力学

主な原動力は、肺炎やレジオネラ関連疾患の発生率の上昇、迅速かつ高度な診断技術に対する需要の増加、細菌検査における技術の進歩です。

意識の高まりと研究開発への支出の増加が、世界市場の成長を促進しています。

ヘルスケアに対する意識の高まりと投資の増加が、世界市場の成長を後押ししています。例えば、西部地区公衆衛生研修センターは、レジオネラ症予防のための研修の実施に携わっています。CDCの国立環境衛生・免疫・呼吸器疾患センター、国立公衆衛生研究所ネットワーク、アリゾナ大学公衆衛生学部メルとエニッド・ザッカーマンとアリゾナ大学の西部地域トレーニングセンターによって開発されたレジオネラ水管理プログラム上のトレーニングの提供に関与しています。さらに、ヘルスケアへの投資の増加も世界市場の活性化につながっています。例えば、欧州製薬団体連合会によると、2000年、製薬産業からの生産は欧州経済に1275億4百万ユーロ貢献し、2010年には1997億3000万ユーロ、2019年には2932億13百万ユーロ、2020年には310億ユーロに達しています。さらに、研究開発費は2000年に178億4900万ユーロ、2010年に279億2000万ユーロ、2019年に377億5400万ユーロ、2020年に3900億ユーロとなっています。

検査に関連する高いコストと政府の厳しい法律が、レジオネラ検査の世界の成長を抑制します。

発展途上国や低開発国における可処分所得の不足、診断テストの感度の問題、テストに関連する高いコスト、政府の厳格な法律。検査に関連する高いコストは、市場成長の妨げになると思われます。例えば、典型的なコストは、小規模な歯科医院や開業医の200ポンドから中規模の介護施設の500ポンドに及びます。また、政府の厳格な法律の存在も市場の妨げになっています。例えば、COSHH（The Control of Substances Hazardous to Health Regulations）は、生物製剤（レジオネラ菌など）を含むさまざまな有害物質からのリスクを管理するための行動の枠組みを与えています。リスクを特定・評価し、あらゆるリスクをコントロールするために必要な措置を実施することです。L8 Approved Code of Practice（3rd edition）（ACOP）が発行されて以来、事業所と家庭施設の両方の家主に対して、入居者がレジオネラにさらされることによるリスクを評価することが要求されています。

業界の分析

世界のレジオネラ検査レポートは、Porter`s Five Force、イノベーション、新製品発表、価格設定など、様々な業界要因に基づいた市場の詳細な分析を提供します。

COVID-19の影響分析

さらなるCOVID-19の感染拡大を防ぐために強いられたさまざまな制限や規制は、以来世界市場に影響を与え、市場に影響を与えるレジオネラ検査を実行することが困難になっています。さらに、パンデミックはまた、多くの先進国と新興国の経済に影響を与え、それは暴発の間に成長するためにレジオネラ検査市場のために困難になります。

世界のレジオネラ検査レポートでは、約40以上の市場データ表、45以上の図、200ページ（概算）の範囲でのアクセスを提供することになります。

目次

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 認知度の向上
    • 研究開発費の増加
  • 抑制要因
    • 検査に伴う高コスト
    • 厳しい政府政策
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 検査タイプ別

• 尿中抗原検査（UAT）
• 培養法
• 直接蛍光抗体法（DFA）
• ポリメラーゼ連鎖反応（PCR）法
• その他

第8章 アプリケーション別

• 臨床検査法
• 環境検査法

第9章 抗生物質別

• アジスロマイシン
• リファンピン
• キノロン
• その他

第10章 エンドユーザー別

• 病院
• 診断センター
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第12章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク

第13章 企業プロファイル

• Abbott
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Albagaia Ltd
• Aquacert Ltd
• Becton, Dickinson and Company
• BioMerieux SA
• Idexx Laboratories Inc.
• Merck Millipore
• Pacific Water Technology
• Phigenics LLC
• Qiagen NV
• Thermo Fisher Scientific Inc.

第14章 DataM

Market Overview

Legionella Testing Market is expected to grow at a CAGR of 9.7% during the forecasting period (2022-2029).

Legionella is a bacterium that causes a severe form of pneumonia called Legionnaires disease or flu-like illness. Legionella testing aids in detecting the presence of bacteria to help diagnose the cause of a person's pneumonia.

Market Dynamics

The major driving forces are the rising incidence of pneumonia and legionella-related illnesses, increasing demand for rapid and advanced diagnostic techniques, and technological advancements in bacterial testing.

The increasing awareness and growing spending on research and development are driving the global market growth.

The growing awareness and increased investment in healthcare are fueling global market growth. For instance, Western Region Public Health Training Center is involved in providing training for Preventing Legionnaires' Disease: A Training over Legionella Water Management Programs, which is developed by the CDC's National Center for Environmental Health, Immunization and Respiratory Diseases, National Network of Public Health Institutes, College of the Public Health University of Arizona Mel and Enid Zuckerman and The Western Region Training Center at the University of Arizona. Furthermore, the increasing investment in healthcare is also fueling the global market. For instance, according to the European Federation of Pharmaceutical Industries and Associations, in 2000, the production from the pharmaceutical industries contributed €127,504 million to Europe's economy, which reached €199,730 million in 2010, €293,213 million in 2019 and €310,000 million in 2020. Furthermore, the R&D expenditure was €17,849 million in 2000, €27,920 million in 2010, €37,754 million in 2019 and €39,000 million in 2020.

The high costs associated with the tests and strict government laws will restrain the global Legionella Testing growth.

The insufficient disposable income in developing and underdeveloped countries, issues in sensitivity of diagnostic tests, high costs associated with the tests, and strict government laws. The high costs associated with the tests will likely hamper the market growth. For instance, typical costs range from £200.00 for a small dental or GP practice to £500.00 for a medium-sized care home. The presence of strict government laws is also hindering the market. For instance, The Control of Substances Hazardous to Health Regulations (COSHH) gives a framework of actions to control the risk from a range of hazardous substances, including biological agents (e.g., Legionella) - to identify and evaluate the risk and implement any necessary measures to control any risk. Since the L8 Approved Code of Practice (3rd edition) (ACOP) was published, there has been a requirement for landlords of both business premises and domestic premises to evaluate the risks from exposure to Legionella to their tenants.

Industry analysis.

The global legionella testing report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing Etc.

COVID-19 Impact Analysis

Different restrictions and regulations forced to prevent further COVID-19 infection spread have impacted the global market since, making it difficult for people to perform legionella testing affecting the market. Furthermore, the pandemic has also affected many developed and developing countries economies, making it difficult for the legionella testing market to grow during the outburst.

Segment Analysis

Urinary antigen testing is expected to have a large share of the Legionella Testing market during the forecast period (2022-2029).

The Urinary Antigen Test segment is expected to grow rapidly over the forecast period (2022-2029). UAT is a diagnostic tool that offers same-day results. Further, UAT is not resource-specific and technically intensive like the culture tests. Since the urinary antigen test does not require respiratory fluid samples, sensitivity issues are also reduced. Thus, UAT remains the test of choice for clinicians and diagnostic experts primarily because of its ease of handling, rapid testing advantage, increased sensitivity, and specificity. For instance, according to the CDC, it has 70-100% sensitivity and 95-100% specificity. Also, the presence of research and development activities on urinary antigen tests is driving the market. Furthermore, a research study on the novel Legionella urinary antigen test kit for diagnosing Legionella pneumonia showed that it could detect Legionella pneumonia caused by non-L. pneumophila serogroup.

Geographical Analysis

North America is dominating the global legionella testing market.

North America dominated the global legionella testing market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the rising incidence of legionellosis and the presence of key players in the region. For instance, according to the Occupational Safety and Health Administration, around 6,000 Legionnaires' disease cases are reported annually in the United States. U.S. population-based study estimated that 8,000-18,000 people are hospitalized yearly with Legionnaires' disease. Furthermore, most market key players have a large portion of the global market, such as Becton, Dickinson and Company, Idexx Laboratories Inc., Phigenics LLC, Thermo Fisher Scientific Inc. and Abbott, ensure that North America commands the global legionella testing market. Moreover, North America has the most advanced and robust healthcare infrastructure and better healthcare cost reimbursement policies.

Competitive Landscape

The major players operating in the global legionella testing market are Albagaia Ltd, Aquacert Ltd, Becton, Dickinson and Company, BioMerieux SA, Idexx Laboratories Inc., Merck Millipore, Pacific Water Technology, Phigenics LLC, Abbott, Qiagen NV, and Thermo Fisher Scientific Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the legionella testing market globally. For instance, on February 23, 2022, Thermo Fisher Scientific Inc. and Moderna entered a long-term collaboration.

Abbott

Overview:

Abbott Laboratories is a leading American healthcare and medical devices innovator and producer headquartered in Illinois, United States, established in 1888. Abbott Laboratories is currently involved in dealing with medical devices, diagnostics, branded generic medicines and nutritional products.

Product Portfolio:

The product portfolio of Abbott for Legionella Testing has BINAX™ LEGIONELLA URINARY ANTIGEN EIA, Etc.

The global legionella testing report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Awareness
    • 4.1.1.2. Growing Research and Development Spending
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost Associated with Tests
    • 4.1.2.2. Strict Government Policies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Test Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment
  • 7.1.2. Market Attractiveness Index, By Test Type Segment
• 7.2. Urinary Antigen Test (UAT)
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Culture Methods
• 7.4. Direct Fluorescent Antibody Test (DFA)
• 7.5. Polymerase Chain Reaction (PCR)
• 7.6. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 8.1.2. Market Attractiveness Index, By Application Segment
• 8.2. Clinical Testing Methods
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Environmental Testing Methods

9. By Antibiotics

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotics Segment
  • 9.1.2. Market Attractiveness Index, By Antibiotics Segment
• 9.2. Azithromycin
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Rifampin
• 9.4. Quinolones
• 9.5. Others

10. By End-user

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
  • 10.1.2. Market Attractiveness Index, By End-user Segment
• 10.2. Hospitals
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 10.3. Diagnostic centers
• 10.4. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
  • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. The U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
  • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. The U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

• 12.1. Key Developments and Strategies
• 12.2. Company Share Analysis
• 12.3. Product Benchmarking

13. Company Profiles

• 13.1. Abbott
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. Albagaia Ltd
• 13.3. Aquacert Ltd
• 13.4. Becton, Dickinson and Company
• 13.5. BioMerieux SA
• 13.6. Idexx Laboratories Inc.
• 13.7. Merck Millipore
• 13.8. Pacific Water Technology
• 13.9. Phigenics LLC
• 13.10. Qiagen NV
• 13.11. Thermo Fisher Scientific Inc.

LIST NOT EXHAUSTIVE

14. DataM

• 14.1. Appendix
• 14.2. About Us and Services
• 14.3. Contact Us